Literature DB >> 21251541

Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices.

Ronald L Pisoni1, Jennifer L Bragg-Gresham, Douglas S Fuller, Hal Morgenstern, Bernard Canaud, Francesco Locatelli, Yun Li, Brenda Gillespie, Robert A Wolfe, Friedrich K Port, Bruce M Robinson.   

Abstract

BACKGROUND: Hemodialysis patients with larger hemoglobin level fluctuations have higher mortality rates. We describe facility-level interpatient hemoglobin variability, its relation to patient mortality, and factors associated with facility-level hemoglobin variability or achieving hemoglobin levels of 10.5-12.0 g/dL. Facility-level hemoglobin variability may reflect within-patient hemoglobin variability and facility-level anemia-control practices. STUDY
DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Data from the Dialysis Outcomes and Practice Patterns Study (DOPPS; 26,510 hemodialysis patients, 930 facilities, 12 countries, 1996-2008) and from the Centers for Medicare & Medicaid Services (CMS; 193,291 hemodialysis patients, 3,741 US facilities, 2002). PREDICTORS: Standard deviation (SD) in single-measurement hemoglobin levels in hemodialysis patients in facility cross-sections (facility-level hemoglobin SD); patient characteristics; facility practices. OUTCOMES: Patient-level mortality; additionally, facility practices correlated with facility-level hemoglobin SD or patient hemoglobin levels of 10.5-12.0 g/dL.
RESULTS: Facility-level hemoglobin SD varied more than 5-fold across DOPPS facilities (range, 0.5-2.7 g/dL; mean, 1.3 g/dL) and by country (range, 1.1 in Japan-DOPPS [2005/2006] to 1.7 g/dL in Spain-DOPPS [1998/1999]), with substantial decreases seen in many countries from 1998 to 2007. Facility-level hemoglobin SD was related inversely to patient age, but was associated minimally with more than 30 other patient characteristics and facility mean hemoglobin levels. Several anemia management practices were associated strongly with facility-level hemoglobin SD and having a hemoglobin level of 10.5-12.0 g/dL. When examined in CMS data, facility-level hemoglobin SD was positively associated with within-patient hemoglobin SD during the prior 6 months. Patient mortality rates were higher with greater facility-level hemoglobin SD (DOPPS: HR, 1.08 per 0.5-g/dL greater facility-level hemoglobin SD [95% CI, 1.02-1.15; P = 0.006]; CMS: HR, 1.16 per 0.5-g/dL greater facility-level hemoglobin SD [95% CI, 1.11-1.21; P < 0. 001]). LIMITATIONS: Residual confounding.
CONCLUSIONS: Facility-level hemoglobin SD was associated strongly and positively with patient mortality, not tightly linked to numerous patient characteristics, but related strongly to facility anemia management practices. Facility-level hemoglobin variability may be modifiable and its optimization may improve hemodialysis patient survival. Copyright Â
© 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21251541     DOI: 10.1053/j.ajkd.2010.11.003

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  18 in total

1.  Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.

Authors:  Michel Jadoul; Jyothi Thumma; Douglas S Fuller; Francesca Tentori; Yun Li; Hal Morgenstern; David Mendelssohn; Tadashi Tomo; Jean Ethier; Friedrich Port; Bruce M Robinson
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

Review 2.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

3.  Variation in nephrologist visits to patients on hemodialysis across dialysis facilities and geographic locations.

Authors:  Kevin F Erickson; Kelvin B Tan; Wolfgang C Winkelmayer; Glenn M Chertow; Jay Bhattacharya
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 8.237

4.  Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis.

Authors:  Keiichi Sumida; Charles Dyer Diskin; Miklos Z Molnar; Praveen K Potukuchi; Fridtjof Thomas; Jun Ling Lu; Connie M Rhee; Elani Streja; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Am J Nephrol       Date:  2017-11-07       Impact factor: 3.754

5.  Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis.

Authors:  Juan José Pérez-Ruixo; Mercedes Cucala-Ramos; Ester García-Gonzalo; Beatriz Del Val Romero; Neus Valveny
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

6.  Dialysis: Hypokalaemia and cardiac risk in peritoneal dialysis patients.

Authors:  Bonnie Ching-Ha Kwan; Cheuk-Chun Szeto
Journal:  Nat Rev Nephrol       Date:  2012-07-17       Impact factor: 28.314

7.  Effect of frequency of intravenous iron administration on hemoglobin variability in maintenance hemodialysis patients.

Authors:  Li Wan; Dongliang Zhang
Journal:  Int Urol Nephrol       Date:  2018-06-26       Impact factor: 2.370

Review 8.  Center-Centered in a Patient-Centered World?

Authors:  Thyago de Moraes; Jeffrey Perl
Journal:  Perit Dial Int       Date:  2016-09-10       Impact factor: 1.756

9.  The MAINTAIN study--managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin.

Authors:  Bruno Watschinger; Hermann Salmhofer; Sabine Horn; Ulrich Neyer; Tatjana Wiesinger; Martin Wiesholzer; Helmut Erb; Christine Jaeger; Margit Hemetsberger; Alexander R Rosenkranz
Journal:  Wien Klin Wochenschr       Date:  2013-01-09       Impact factor: 1.704

10.  Anemia Management in the China Dialysis Outcomes and Practice Patterns Study.

Authors:  Li Zuo; Mia Wang; Fanfan Hou; Yucheng Yan; Nan Chen; Jiaqi Qian; Mei Wang; Brian Bieber; Ronald L Pisoni; Bruce M Robinson; Shuchi Anand
Journal:  Blood Purif       Date:  2016-03-31       Impact factor: 2.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.